Most osteoporosis treatment slows loss. Only three drugs currently add bone: teriparatide, abaloparatide and romosozumab. Abaloparatide is the daily injection in that group, and it occupies a specific place — for women whose fracture risk is high enough that preserving what remains is not enough.
How it builds bone
Abaloparatide is an analogue of parathyroid hormone-related protein and acts on the PTH1 receptor. Continuous exposure to parathyroid hormone breaks bone down; intermittent exposure, which is what a once-daily injection produces, stimulates osteoblasts to build it. That paradox is the basis of the entire anabolic class.
Abaloparatide binds preferentially to a particular conformation of the receptor, producing a shorter signalling burst than teriparatide. The practical consequence is a smaller rise in blood calcium — the difference that most often decides between the two drugs.
What the ACTIVE trial showed
ACTIVE enrolled around 2,460 postmenopausal women with osteoporosis and randomised them to abaloparatide, teriparatide or placebo for 18 months. Against placebo, abaloparatide reduced new vertebral fractures by 86% and non-vertebral fractures by 43%. Spine bone density rose by roughly 11% and total hip by about 4%.
The extension study, ACTIVExtend, moved participants onto alendronate for a further 24 months. Fracture reduction was maintained, which is the practical demonstration that the sequence works — and the reason the follow-on drug is not treated as optional.
Who it is for
Approved for postmenopausal women at high risk of fracture: a previous fragility fracture, multiple risk factors, or failure of or intolerance to other treatments. It is also approved for men with osteoporosis at high risk. It is not appropriate for someone with mild osteopenia and no fracture history, where the risk-benefit balance does not support a daily injection.
It is avoided in people with elevated blood calcium, hyperparathyroidism, previous radiation to the skeleton, or bone metastases.
The osteosarcoma warning that was removed
Abaloparatide originally carried a boxed warning about osteosarcoma, based on rats given very high doses for most of their lifespan. Long-term human surveillance of teriparatide, in use since 2002, found no increased osteosarcoma rate, and the FDA removed the boxed warning from this class in 2021. The lifetime duration limits remain, but the cancer warning that shaped a decade of prescribing decisions is gone.
Side effects and practicalities
Dizziness on standing
The most distinctive one. Abaloparatide can cause a transient drop in blood pressure on standing, usually within four hours of the dose. Taking it where you can sit or lie down afterwards, at least for the first several doses, is the standard advice.
Blood calcium
Calcium rises less than with teriparatide, but it is still monitored. Pre-existing hypercalcaemia is a contraindication rather than something to manage around.
Injection and storage
One subcutaneous injection daily into the abdomen, rotating sites. The pen is refrigerated before first use and then kept at room temperature for up to 30 days. Common local effects are redness and mild pain at the site.
Nausea, headache and palpitations
All reported in trials, generally mild and often settling over the first weeks.
Abaloparatide or teriparatide?
| Abaloparatide | Teriparatide | |
|---|---|---|
| Duration limit | 18 months lifetime | 24 months lifetime |
| Hypercalcaemia | Less frequent | More frequent |
| Track record | Approved 2017 | Approved 2002, far more real-world data |
| Storage | Room temperature up to 30 days after first use | Refrigerated throughout |
| Biosimilars | None | Available, lowering cost |
Storage is a more common deciding factor than it sounds — a pen that survives a day out of the fridge changes what travel looks like over 18 months.
What follows the course
The 18 months end and the drug stops permanently. Without an antiresorptive started promptly afterwards, the bone built is lost within roughly a year. This is the single most important thing to have arranged in advance, and it applies equally to romosozumab. See our overview of osteoporosis medications compared and, if you are already on treatment, what happens when you stop.
The first month, practically
Learning the pen
The first injection is normally taught in a clinic. The pen delivers a fixed dose into the abdomen; sites are rotated to avoid local reactions. It is refrigerated until first use, then kept at room temperature and discarded after 30 days regardless of how much remains — that expiry is a real one, not a conservative estimate.
Timing the dose around dizziness
Blood pressure can dip on standing within four hours of injecting. Most people settle into injecting in the evening, seated, with nothing that requires standing immediately afterwards. If dizziness persists past the first few weeks, it is worth reporting rather than tolerating — it is manageable, and it is also a reason some people stop unnecessarily.
Nausea and headache
Both are common early and usually fade. Injecting after food helps some people with the nausea. Neither is a reason to stop in the first fortnight unless severe.
What is monitored
Blood calcium is checked, less intensively than with teriparatide but still checked. Kidney function and vitamin D status are reviewed. Density is not usually re-scanned before eighteen months, because shorter intervals cannot distinguish real change from scanner variation.
Where it sits in a treatment sequence
Anabolic-first is now the preferred order for people at very high fracture risk. Building bone and then protecting it produces larger and more durable gains than suppressing turnover first and trying to build afterwards. Someone who has taken bisphosphonates for years will respond less to an anabolic drug than someone who has not, because the remodelling it acts on is already slowed.
Practically, that means abaloparatide is usually considered early in a high-risk plan rather than as a last resort after other drugs have failed — a shift from how these drugs were positioned a decade ago.
Cost and access
Abaloparatide is a specialty pharmacy product, and coverage typically requires documentation of high fracture risk plus, in many plans, a trial of or contraindication to bisphosphonates. Unlike teriparatide, it has no biosimilar, so there is no cheaper equivalent — that is a genuine practical difference between the two when cost is the constraint. The manufacturer operates a savings programme, and specialty pharmacies usually handle the prior authorization directly with the prescriber.
Because treatment is capped at eighteen months, total cost is bounded rather than open-ended. Our cost and coverage estimator walks through how to read your own plan.
Questions worth asking before starting
- Is my fracture risk high enough to warrant a daily injection? A previous fragility fracture usually settles this; osteopenia without one usually does not.
- Abaloparatide or teriparatide? Hypercalcaemia history, storage practicalities and cost — including whether a biosimilar is available to you — are the three things that usually decide it.
- What follows the eighteen months, and when does it start? The handover should be planned at the beginning, not at the end.
- Have I taken bisphosphonates long-term? If so, expect a smaller response and discuss whether the sequence should differ.
- Is my calcium and vitamin D adequate? Both are corrected before starting, not alongside.
What eighteen months can and cannot do
The honest frame is that anabolic treatment buys a step change in bone density and a substantial reduction in fracture risk during a defined window — and that the window closes. It does not cure osteoporosis, and it does not remove the need for the things that were true beforehand: resistance and weight-bearing exercise, adequate protein, calcium and vitamin D, and attention to fall risk, which contributes to most fractures alongside weak bone.
Our guides to exercise for bone density and calcium and vitamin D cover the parts that continue after the injections stop.